Alnylam Pharmaceuticals, Inc.

ALNY · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$278-$440-$1,131-$853
Dep. & Amort.$57$97$86$90
Deferred Tax-$107$0$0-$56
Stock-Based Comp.$272$222$231$166
Change in WC-$214$11-$36-$163
Other Non-Cash$262$215$309$174
Operating Cash Flow-$8$104-$541-$642
Investing Activities
PP&E Inv.-$34-$62-$72-$76
Net Acquisitions$0$0$0$0
Inv. Purchases-$1,712-$1,824-$1,977-$1,656
Inv. Sales/Matur.$1,572$1,554$2,232$1,464
Other Inv. Act.$58-$4-$13-$4
Investing Cash Flow-$117-$336$169-$273
Financing Activities
Debt Repay.$0$0$254$500
Stock Issued$303$147$259$246
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$9$25-$88$501
Financing Cash Flow$294$172$426$1,247
Forex Effect-$15$6-$7-$9
Net Chg. in Cash$154-$54$46$323
Supplemental Information
Beg. Cash$815$869$822$499
End Cash$969$815$869$822
Free Cash Flow-$43$42-$613-$718